Affymax, Inc. announced that it will retain a bank to evaluate strategic alternatives for the organization, including the sale of the company or its assets, or a corporate merger. Affymax is considering all possible alternatives, including further restructuring activities, wind-down of operations or even bankruptcy proceedings. Affymax announced that it will reduce its workforce by 75% as part of a plan to focus the company's resources on the ongoing investigation of reported hypersensitivity reactions in patients receiving OMONTYS Injection.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +6.67% | 0.00% | +33.33% |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 59.59K | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+49.34% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- AFFY Stock
- News Affymax, Inc.
- Affymax Seeks Strategic Alternatives